newsfilter
← Latest News
GlobeNewswire·

Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results

Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients continues; additional data update expected mid-year 2022 Two Phase 2 (FREEDOM-2 and FREEDOM-3) clinical trials of FCR001 initiated in delayed tolerance and scler